Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Clonal hematopoiesis in elderly twins: concordance, discordance and mortality

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Epigenetic therapy in hematological cancers

    Research output: Contribution to journalReviewResearchpeer-review

  • Simone Ferrero
  • Davide Rossi
  • Andrea Rinaldi
  • Alessio Bruscaggin
  • Valeria Spina
  • Christian W Eskelund
  • Andrea Evangelista
  • Riccardo Moia
  • Ivo Kwee
  • Christina Dahl
  • Alice Di Rocco
  • Vittorio Stefoni
  • Fary Diop
  • Chiara Favini
  • Paola Ghione
  • Abdurraouf Mokhtar Mahmoud
  • Mattia Schipani
  • Arne Kolstad
  • Daniela Barbero
  • Domenico Novero
  • Marco Paulli
  • Alberto Zamò
  • Mats Jerkeman
  • Maria Gomez da Silva
  • Armando Santoro
  • Annalia Molinari
  • Andres Ferreri
  • Kirsten Grønbæk
  • Andrea Piccin
  • Sergio Cortelazzo
  • Francesco Bertoni
  • Marco Ladetto
  • Gianluca Gaidano
View graph of relations

In recent years, the outcome of mantle cell lymphoma has improved, especially in younger patients, receiving cytarabine-containing chemoimmunotherapy and autologous stem cell transplantation. Nevertheless, a proportion of mantle cell lymphoma patients still experience early failure. To identify biomarkers anticipating failure of intensive chemotherapy in mantle cell lymphoma, we performed target resequencing and DNA profiling of purified tumor samples collected from patients enrolled in the prospective FIL-MCL0208 phase III trial (high-dose chemoimmunotherapy followed by autologous transplantation and randomized lenalidomide maintenance). Mutations of KMT2D and disruption of TP53 by deletion or mutation associated with an increased risk of progression and death, both in univariate and multivariate analysis. By adding KMT2D mutations and TP53 disruption to the MIPI-c backbone, we derived a new prognostic index, the MIPI-genetic. The MIPI-g improved the model discrimination ability compared to the MIPI-c alone, defining three risk groups: i) low-risk patients (4-years progression free survival and overall survival of 72.0% and 94.5%); ii) intermediate-risk patients (4-years progression free survival and overall survival of 42.2% and 65.8%) and iii) high-risk patients (4-years progression free survival and overall survival of 11.5% and 44.9%). Our results: i) confirm that TP53 disruption identifies a high-risk population characterized by poor sensitivity to conventional or intensified chemotherapy; ii) provide the pivotal evidence that patients harboring KMT2D mutations share the same poor outcome as patients harboring TP53 disruption; and iii) allow to develop a tool for the identification of high-risk mantle cell lymphoma patients for whom novel therapeutic strategies need to be investigated. (Trial registered at clinicaltrials.gov identifier: NCT02354313).

Original languageEnglish
JournalHaematologica
Pages (from-to)1-49
ISSN0390-6078
DOIs
Publication statusPublished - 19 Sep 2019

ID: 59005753